Abstract Background: Cell free deoxyribonucleic acid (cf-DNA) is now emerging as a useful tool for non-invasive diagnostic methods related to a wide range of clinical conditions including autoimmune diseases.
Introduction
Circulating cell-free deoxyribonucleic acid (cf-DNA), defined as extracellular DNA occurring in blood serum or plasma, has been widely studied and is considered as a potential biomarker for the detection and monitoring of various human diseases such as stroke [1] , myocardial infarction [2] , sepsis [3] , acute pancreatitis [4] , as well as cancer [5] . Circulating cf-DNA molecules are present in only limited amounts in blood of healthy individuals, since dying cells and remnants of dead cells are efficiently removed, mainly in the liver [6] . Reactive oxygen species are implicated as a cause of damage to DNA, including breaking of single and double strands, releasing of free nucleobases, chemical changes of nucleobases, and modification of sugar moieties [7] . The first report on the presence of circulating cf-DNA was published decades ago in 1948 [8] , they detected the presence of free nucleic acids in plasma. They were able to detect free DNA and RNA in the plasma of healthy individuals and patients. Unfortunately, their work passed unnoticed because of lack of clear understanding about circulating nucleic acid at that time. Later it became clear that analyzing and quantitating cell-free plasma DNA could serve as a valuable diagnostic tool [9] .
Rheumatoid arthritis (RA) is an inflammatory, destructive joint disease in which a broad range of extra-articular manifestations may occur. Serological tests, most notably the detection of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF), play an important role in diagnosing RA. The ACPA were found in up to 75% of RA patients [10] . RF is present in 60-90% of patients with established RA and in up to 50% of patients with early RA [11] . Anti-nuclear antibodies (ANAs) occur in approximately 30% of patients with RA, as determined by nuclear immunofluorescence. Because complexes of anti-DNA antibodies with microbial or self DNA are implicated in the activation of B cells by Toll-like receptors and surface IgM RF, it is possible to hypothesize that anti-DNA antibodies and DNA represent such an antibody-antigen system in vivo [12] . Although, the introduction of ACPA and RF tests has greatly contributed to improving the early diagnosis of RA, additional molecular markers are needed, to identify the seronegative patients, to differentiate between disease phenotypes, to predict responsiveness to treatment and to improve prognosis [13] .
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease with a complex pathogenesis involving multiple genetic and environmental factors. The disease is characterized by enhanced autoantibody production, abnormalities in function of immune-inflammatory system and inflammatory manifestations in several organs [14] . Cell death has been regarded as an important event in the pathogenesis as it leads to release of antigens as nucleic acids for immune complex formation and that DNA-antibody complexes in the circulation are one of the hallmarks of SLE [15] . It is well known that auto-antibodies can target DNA and the DNA auto-antibody complex in the circulation plays a crucial role in SLE [16] and may trigger a cascade of immune responses against body tissue in SLE patients [17] . In a study on Egyptian SLE patients there was an apparent higher incidence of secondary antiphospholipid syndrome in those with positive anti-DNA [18] . The anti-dsDNA may serve as potential reliable and non invasive markers of SLE disease activity and renal involvement in Sharkia governorate and may help in avoiding unnecessary renal biopsies [19] . In another study, of the anti-chromatin autoantibodies, anti-nucleosome and not anti-DNA were associated with active lupus disease and correlate with the degree of renal affection [20] . The aim of this study was to measure the levels of plasma cf-DNA in patients with RA and SLE compared with levels in healthy subjects and to find any correlation with disease activity in both diseases.
Patients and methods
We evaluated 30 RA and 35 SLE patients selected from the outpatient clinics and inpatient units of Rheumatology, Physical Medicine and Rehabilitation Department, Zagazig University Hospitals, during the period from May 2014 to December 2015. Age and gender matched 25 healthy volunteer subjects were included in this study as control. A written informed consent was obtained from patients after explanation of the purpose and procedures of the study. All RA patients fulfilled the 2010 Classification Criteria for RA [21] . All SLE patients satisfied the Systemic Lupus International Collaborating Clinics (SLICC) revised SLE classification criteria [22] . The disease activity in RA patients was evaluated according to Disease Activity Score 28 (DAS28) [23] and in SLE according to the SLE disease activity index 2000 (SLEDAI-2K) [24] . Patients with a history of stroke, cancer, myocardial infarction, hepatic, cardiac or renal impairment and diabetic patients were excluded. Patients with other autoimmune diseases were also excluded. The study was approved by the ethics committee of the Zagazig University Hospitals, Faculty of Medicine, Zagazig University.
All Patients were subjected to complete history taking with stress on disease duration, complete physical and musculoskeletal examination, Health Assessment Questionnaire (HAQ) [25] assessment, routine laboratory investigations including complete blood count (CBC), liver and kidney function tests, 24 h urine protein for SLE patients, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF) and serum complement C3 and C4 levels. The ANA and anti-double stranded DNA (anti-dsDNA) were measured by indirect immunofluorescence assay (IIF) (Immuno-Diagnostic USA).
Plasma cf-DNA analysis by real-time quantitative polymerase chain reaction (PCR): samples were taken from both patients and controls. Five ml of venous blood was collected under complete aseptic conditions and put into sterile vacutainer EDTA tubes. The samples were processed immediately. The blood samples were centrifuged at 1600g for 10 min. Plasma layer was obtained and transferred to new sterile tubes. A further centrifugation step at 1600g for 10 min was performed to spin down any insoluble remnants in the plasma. Plasma cell-free DNA was then extracted from the 400 ll of plasma sample using the high pure PCR template preparation kit (Roche Diagnostics, Germany), following the manufacturers protocol. The DNA preparations were eluted in 100 ll elution buffers and the purified DNA was stored at À80°C until further use. For analyzing cf-DNA, the GAPDH (glyceraldehydes-3-phosphate dehydrogenase) housekeeping gene has been used with forward 5 0 -CCCCACACACATG CACTT-ACC-3 0 , reverse 5 0 -CCTAGTCCCAGGGCTTT GATT-3 0 primers and 5 0 -MGB-TAGGAAGGACAGG CAAC-VIC-3 0 as the probe [26] . Five ll of DNA elution was used as a template for the real-time PCR analysis. The PCR was performed using the ABI step one (Applied Biosystems, ABI). The real-time PCR was carried out in 25 ll of total reaction volume containing 5 ll of DNA, 12.5 ll of TaqMan Universal PCR Master Mix, four primers, and two probes using two-minute incubation at 50°C. The reaction was processed by an initial denaturation step at 95°C for 10 min and 40 cycles of 1 min at 60°C and 15 s at 95°C. For the multiplex TaqMan amplification of the concentration of primers and probes was optimized. The optimal concentration of the primers and probes for duplex real-time PCR is 0.6 lM for each primer and 0.4 lM for each probe [27] . The positive reaction was detected by the accumulation of a fluorescent signal. The cycles required for the fluorescent signal to cross the threshold are defined as cycle threshold (CT). The CT values can also be converted into quantities according to standard curves generated by dilution of human genomic DNA with a known concentration for generating the standard curves [28, 29] .
Statistical analysis
IBM SPSS statistics (V. 23.0, IBM Corp., USA, 2015) was used for data analysis. Data were expressed as mean ± SD for quantitative parametric measures in addition to both number and percentage for categorized data. Comparison between two independent mean groups for parametric data was done using Student t test and among more than 2 patient groups using an Analysis of Variance (ANOVA). Chi-square test was used to study the association between each 2 variables or comparison between 2 independent groups as regards the categorized data. The probability of error at 0.05 was considered significant, while at 0.01 and 0.001 was considered highly significant.
Results
The study included three groups: RA group (24 women and 6 men; F:M 4:1) with a mean age of 36.8 ± 9.6 years (20-52 years) and mean disease duration of 8.3 ± 1.1 years (7-10 years), SLE group (31 women and 4 men; F:M 7.75:1) with a mean age of 35.6 ± 8.8 years (22-50 years) and mean disease duration of 8.1 ± 0.87 years (7-9 years) and control group (20 women and 5 men; F:M 4:1) with a mean age of 37.8 ± 9.7 years (21-57 years). The control group was age (p = 0.62) matched with the 2 groups of patients.
Baseline clinical and laboratory variables of the patients are shown in Table 1 . There was a highly significant increase in the cf-DNA level in SLE patients (17.33 ± 2.4 ng/ml) and RA patients (11.15 ± 2.3 ng/ml) compared to the level in the control (4.15 ± 1.4 ng/ml) (p = 0.0005) (Fig. 1) .
There was a significant correlation between cf-DNA and disease variables in RA patients (Table 2) including ESR, CRP, and DAS-28 ( Fig. 2) while not with patient age, disease duration and HAQ. Also, significant correlations were found between cf-DNA and disease variables in SLE patients (Table 3) including ESR, CRP, anti-ds-DNA titer, C3 level, C4 level and total SLEDAI (Fig. 3) , while, there were no correlations between cf-DNA levels and patient age and disease duration.
Discussion
The origin and exact mechanism of cf-DNA release are still controversial. Accumulation of cf-DNA in plasma might result from an excessive release of DNA caused by massive cell death or inefficient elimination of dead cells and during inflammation. Thus, the concentration of plasma cf-DNA might reflect the magnitude of cell damage and inflammation. The free mitochondrial DNA could promote endothelial dysfunction, as well as other side effects on the vascular system through the activation of the toll-like receptor 9 (TLR9). TLR9 is expressed in different cell types (e.g., T or B lymphocytes, mastocytes, and epithelial and endothelial cells). It is localized intracellularly and recognizes non-methylated dinucleotides of viral, bacterial, and mitochondrial DNA [30] . Alteration of cf-DNA levels has been reported for autoimmune diseases such as SLE, systemic sclerosis, Sjo¨gren's syndrome [31] and RA [32] .
In the present study a highly significant difference was found between each of RA and SLE patients, and controls as regards the levels of cf-DNA. Our results agreed with that of Zhong and his colleagues [32] who found that the serum levels of cf-DNA were significantly higher in the RA group than in the control. Patients with RA showed a highly substantial increase in circulating DNA concentrations in the plasma and in the serum, which were in the high range of those reported in neoplasia or preeclampsia. Dunaeva et al. evaluated the concentration of cf-DNA from sera of patients with early RA, established RA, relapsing-remitting multiple sclerosis patients and healthy subjects. Their results revealed that reduced levels of cf-DNA were more observed in patients with established RA. They reported that measurement of cf-DNA can distinguish established from early RA patients [13] . Thus, cf-DNA may serve as a biomarker in RA. In contrast cf-DNA was high in our RA patients with established disease and this can be explained with their active disease.
Our results showed significant correlation between cf-DNA levels and the disease variables including ESR, CRP and DAS28 in RA patients. Our results agreed with Leon et al. [33] , who found higher concentrations of free DNA in both plasma and synovial fluid in RA patients than in healthy subjects and it correlated with the symptom severity and the level of the tissue damage. Our results showed significant correlation between cf-DNA levels and the disease variables in SLE patients including ESR, CRP, anti-ds-DNA titer, C3, C4 and SLEDAI. Our results agreed with Atamaniuk and his coworkers [34] , who demonstrated a significantly increased cf-DNA plasma level in SLE patients. However, they found no correlation between disease activity and anti-dsDNA, antissDNA and anti-nucleosome antibody concentrations. Our results agreed with Zhang and his co-workers [35] , who found a significantly higher cf-DNA concentration in SLE patients than that observed in the healthy control especially those with active lupus nephritis. Our results agreed also with that of Hendy and her co-workers [36] , who found a significantly higher serum level of cf-DNA in SLE patients compared with healthy controls and a positive correlation was found with parameters of disease activity. Furthermore, they found a significant reduction in serum level of cf-DNA after specific drug therapy for SLE disease indicating a prognostic value. Similarly, Tug and her colleagues showed a significantly higher cf-DNA concentration in SLE patients compared to control [37] . Our findings support that the measurement of cf-DNA appear to be a useful marker of disease activity in addition to the laboratory tests used in SLE and RA. Future longitudinal studies on a larger number of patients are needed to verify the presented results with in-depth studying of the relation to clinical manifestations.
